Clinical outcome of pertussis in Sweden: Association with pulsed-field gel electrophoresis profiles and serotype

APMIS

Volumn 115, Issue 6, 2007, Pages 736-742

  Advani, Abdolreza ^a,b   Gustafsson, Lennart ^a   Carlsson, Rose Marie ^a   Donnelly, Declan ^a   Hallander, Hans O ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

Acellular pertussis vaccine; Bordetella pertussis; Clinical outcome; Pulsed field gel electrophoresis; Whooping cough

Indexed keywords

PERTUSSIS VACCINE;

ARTICLE; BACTERIAL STRAIN; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; FOLLOW UP; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; PERTUSSIS; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; SEROTYPE; STATISTICAL SIGNIFICANCE; SWEDEN; TREATMENT OUTCOME; VACCINATION;

BORDETELLA PERTUSSIS; CHILD; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; ELECTROPHORESIS, GEL, PULSED-FIELD; HUMANS; POPULATION SURVEILLANCE; SEROTYPING; SWEDEN; VACCINATION; WHOOPING COUGH;

EID: 34249773983     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2007.apm_628.x     Document Type: Article

References (32)

1. von Konig CH, Halperin S, Riffelmann M, Guiso N. Pertussis of adults and infants. Lancet Infect Dis 2002 2 : 744 50.
2. Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin. Microbiol. Rev. 2005 18 : 326 82.
3. Greenberg DP, von Konig CH, Heininger U. Health burden of pertussis in infants and children. Pediatr Infect Dis J 2005 24 (Suppl S39 43.
4. Cherry JD. The epidemiology of pertussis and pertussis immunization in the United Kingdom and the United States: a comparative study. Curr Probl Pediatr 1984 14 : 1 78.
5. Gustafsson L, Hessel L, Storsaeter J, Olin P. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Pediatrics 2006 118 : 978 84.
6. Forsyth K, Tan T, von Konig CH, Caro JJ, Plotkin S. Potential strategies to reduce the burden of pertussis. Pediatr Infect Dis J 2005 24 (Suppl S69 74.
7. Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 2005 24 (Suppl S58 61.
8. Hallander HO, Advani A, Donnelly D, Gustafsson L, Carlsson RM. Shifts of Bordetella pertussis variants in Sweden from 1970 to 2003, during three periods marked by different vaccination programs. J Clin Microbiol 2005 43 : 2856 65.
9. Lee YS, Yang CY, Lu CH, Tseng YH. Molecular epidemiology of Bordetella pertussis isolated in Taiwan, 1992-1997. Microbiol Immunol 2003 47 : 903 9.
10. Cassiday P, Sanden G, Heuvelman K, Mooi F, Bisgard KM, Popovic T. Polymorphism in Bordetella pertussis pertactin and pertussis toxin virulence factors in the United States, 1935-1999. J Infect Dis 2000 182 : 1402 8.
11. Fry NK, Neal S, Harrison TG, Miller E, Matthews R, George RC. Genotypic variation in the Bordetella pertussis virulence factors pertactin and pertussis toxin in historical and recent clinical isolates in the United Kingdom. Infect Immun 2001 69 : 5520 8.
12. Gzyl A, Augustynowicz E, van Loo I, Slusarczyk J. Temporal nucleotide changes in pertactin and pertussis toxin genes in Bordetella pertussis strains isolated from clinical cases in Poland. Vaccine 2001 20 : 299 303.
13. Hardwick TH, Cassiday P, Weyant RS, Bisgard KM, Sanden GN. Changes in predominance and diversity of genomic subtypes of Bordetella pertussis isolated in the United States, 1935 to 1999. Emerg Infect Dis 2002 1 : 44 9.
14. Mooi FR, He Q, van Oirschot H, Mertsola J. Variation in the Bordetella pertussis virulence factors pertussis toxin and pertactin in vaccine strains and clinical isolates in Finland. Infect Immun 1999 67 : 3133 4.
15. Peppler MS, Kuny S, Nevesinjac A, Rogers C, de Moissac YR, Knowles K, et al. Strain variation among Bordetella pertussis isolates from Quebec and Alberta provinces of Canada from 1985 to 1994. J Clin Microbiol 2003 41 : 3344 7.
16. Weber C, Boursaux-Eude C, Coralie G, Caro V, Guiso N. Polymorphism of Bordetella pertussis isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years. J Clin Microbiol 2001 39 : 4396 403.
17. Advani A, Donnelly D, Gustafsson L, Hallander HO. Changes in the Swedish Bordetella pertussis population from 1997 to 2004 during vaccination with acellular pertussis vaccines. APMIS 2007 in press.
18. Gustafsson L, Hallander HO, Olin P. SEVEN YEAR REPORT, Pertussis surveillance in Sweden, Progress Report October 1997 - September 2004. In : In:. http: //www.smittskyddsinstitutet.se/upload/PDF-filer/seven-year-report.pdf, 2005.
19. Bergström M, Romanus V. Vaccinationsstatistik från barnavårdscentralerna, insamlad januari 2005, gällande barn födda 2002. In: http: //www.smittskyddsinstitutet.se/upload/5216/ BVCjan2005-050526x.pdf, editor. Swedish Institut for Infectious Disease (SMI) 2005 (in Swedish).
20. Olin P, Rasmussen F, Gustafsson L, Hallander HO, Heijbel H. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet 1997 350 : 1569 77.
21. Advani A, Donnelly D, Hallander H. Reference system for characterization of Bordetella pertussis pulsed-field gel electrophoresis profiles. J Clin Microbiol 2004 42 : 2890 7.
22. Mooi FR, Hallander H, Wirsing von Konig CH, Hoet B, Guiso N. Epidemiological typing of Bordetella pertussis isolates: recommendations for a standard methodology. Eur J Clin Microbiol Infect Dis 2000 19 : 174 81.
23. Van Buynder PG, Owen D, Vurdien JE, Andrews NJ, Matthews RC, Miller E. Bordetella pertussis surveillance in England and Wales: 1995-7. Epidemiol Infect 1999 123 : 403 11.
24. Celentano LP, Massari M, Paramatti D, Salmaso S, Tozzi AE. Resurgence of Pertussis in Europe. Pediatr Infect Dis J 2005 24 : 761 5.
25. Crowcroft NS, Stein C, Duclos P, Birmingham M. How best to estimate the global burden of pertussis? Lancet Infect Dis 2003 3 : 413 8.
26. Report A. Epidemiologisk årsrapport 2004. In: http: //www.smittskyddsinstitutet.se/upload/Publikationer/Epi-arsrapport-050623.pdf, editor. Swedish Institute for Infectious Disease Control (SMI); 2004 (in Swedish).
27. WHO. Pertussis surveillance. A global meeting, Geneva, 16-18 October 2000. In: http: //www.who.int/vaccines-documents/DocsPDF01/www605.pdf. 2000.
28. Mooi FR, van Loo IH, King AJ. Adaptation of Bordetella pertussis to vaccination: a cause for its reemergence?. Emerg Infect Dis 2001 7 (Suppl S526 8.
29. Bisgard KM, Christie CD, Reising SF, Sanden GN, Cassiday PK, Gomersall C, et al. Molecular epidemiology of Bordetella pertussis by pulsed-field gel electrophoresis profile: Cincinnati, 1989-1996. J Infect Dis 2001 183 : 1360 7.
30. Heininger U, Frei R, Cherry JD, Stehr K. Comparison of pulsed field gel electrophoresis patterns of Bordetella pertussis isolates from unvaccinated children with severe or mild pertussis. Pediatr Infect Dis J 2004 23 : 211 7.
31. Preston NW. Essential immunogens in human pertussis: the role of fimbriae. Dev Biol Stand 1985 61 : 137 41.
32. WHO. WHO Expert Committee on Biological Standardization, 30th Report. Technical Report Series 1979 638 : 61 5.